ITOS - iTeos Therapeutics, Inc. Stock Price, Fair Value and News

17.95USD+1.23 (+7.36%)Market Closed

Market Summary

USD17.95+1.23

Market Closed

7.36%

ITOS Stock Price

View Fullscreen

ITOS RSI Chart

ITOS Valuation

Market Cap

604.0M

Price/Earnings (Trailing)

-4.46

Price/Sales (Trailing)

47.95

EV/EBITDA

-3.52

Price/Free Cashflow

-5.33

ITOS Price/Sales (Trailing)

ITOS Profitability

EBT Margin

-1037.55%

Return on Equity

-25%

Return on Assets

-21.49%

Free Cashflow Yield

-18.77%

ITOS Fundamentals

ITOS Revenue

Revenue (TTM)

12.6M

Rev. Growth (Yr)

-100%

ITOS Earnings

Earnings (TTM)

-135.3M

Earnings Growth (Yr)

-145.75%

Earnings Growth (Qtr)

-25.09%

Breaking Down ITOS Revenue

Last 7 days

36.2%

Last 30 days

43%

Last 90 days

65.6%

Trailing 12 Months

12.5%

How does ITOS drawdown profile look like?

ITOS Financial Health

Current Ratio

13.51

ITOS Investor Care

Shares Dilution (1Y)

1.00%

Diluted EPS (TTM)

-3.78

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	127.7M	86.0M	66.5M	12.6M
2022	500.0M	539.0M	454.2M	267.6M
2021	9.0M	10.6M	112.6M	352.4M
2020	4.4M	4.8M	5.2M	5.6M
2019	0	0	0	4.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of iTeos Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 05, 2023	mcgrath yvonne	acquired	-	-	31,000	chief scientific officer
Dec 05, 2023	detheux michel	acquired	-	-	30,000	chief executive officer
Dec 05, 2023	gall matthew	acquired	-	-	41,000	chief financial officer
Dec 05, 2023	call matthew	acquired	-	-	44,000	chief operating officer
Oct 12, 2023	gall matthew	bought	41,850	8.37	5,000	chief financial officer
Aug 23, 2023	boxer capital, llc	sold	-5,692,670	16.2648	-350,000	-
Mar 28, 2023	call matthew	acquired	118,667	2.95	40,226	chief operating officer
Jun 09, 2022	hallal david	sold	-22,846	19.51	-1,171	-
Jun 09, 2022	hallal david	acquired	4,953	4.23	1,171	-
Jun 08, 2022	hallal david	acquired	105,087	3.69454	28,444	-

Which funds bought or sold ITOS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 14, 2024	ALLIANCEBERNSTEIN L.P.	reduced	-9.88	47,407	434,161	-%
May 14, 2024	Invesco Ltd.	added	128	747,874	1,153,380	-%
May 14, 2024	FEDERATED HERMES, INC.	reduced	-8.63	4,455	36,692	-%
May 14, 2024	GOLDMAN SACHS GROUP INC	added	21.81	1,454,770	8,125,640	-%
May 14, 2024	PRUDENTIAL FINANCIAL INC	reduced	-29.48	-456,358	3,299,390	-%
May 13, 2024	STRS OHIO	reduced	-51.85	-48,000	70,000	-%
May 13, 2024	Lighthouse Investment Partners, LLC	new	-	333,812	333,812	0.01%
May 13, 2024	UBS Group AG	added	30.5	310,182	806,042	-%
May 13, 2024	Ameritas Investment Partners, Inc.	unchanged	-	6,574	33,336	-%
May 13, 2024	FOX RUN MANAGEMENT, L.L.C.	reduced	-46.52	-101,467	202,472	0.04%

Are Funds Buying or Selling ITOS?

Are funds buying ITOS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ITOS

No. of Funds

Unveiling iTeos Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2024	ecor1 capital, llc	5.4%	1,944,672	SC 13G
Feb 14, 2024	biotechnology value fund l p	1.9%	671,726	SC 13G/A
Feb 13, 2024	vanguard group inc	4.17%	1,490,942	SC 13G/A
Jan 23, 2024	blackrock inc.	11.9%	4,261,745	SC 13G/A
Jan 09, 2024	millennium management llc	2.7%	967,402	SC 13G/A
Oct 24, 2023	millennium management llc	5.8%	2,090,833	SC 13G
Feb 14, 2023	biotechnology value fund l p	2.7%	975,430	SC 13G/A
Feb 14, 2023	rtw investments, lp	0%	0	SC 13G/A
Feb 09, 2023	vanguard group inc	5.11%	1,819,030	SC 13G
Jan 26, 2023	blackrock inc.	12.6%	4,479,421	SC 13G/A

Recent SEC filings of iTeos Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	SC 13D/A	13D - Major Acquisition
May 13, 2024	8-K	Current Report
May 10, 2024	10-Q	Quarterly Report
May 10, 2024	424B5	Prospectus Filed
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Mar 08, 2024	4	Insider Trading

Peers (Alternatives to iTeos Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	22.08%	-1.47%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.34%	-28.23%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-13.63%	-16.32%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	5.96%	-13.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	8.09%	95.42%	-9.91	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-20.37%	-53.19%	-11.98	9.54	394.93%	39.61%
AXSM	3.7B	251.0M	11.93%	-0.48%	-12.39	14.63	73.58%	-86.73%
ARWR	2.8B	240.7M	-7.33%	-42.62%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.36%	-32.87%	-1.4K	3.02	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	8.34%	25.49%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	214.95%	66.21%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	4.53%	306.67%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.99%	24.13%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-6.93%	99.64%	-0.7	7.61	-13.45%	69.54%

iTeos Therapeutics, Inc. News

Latest updates

iTeos Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-	-	-	-	-	12,595,000	53,905,000	19,487,000	41,716,000	152,522,000	240,504,000	104,271,000	2,701,000	4,915,000	678,000	2,299,000	1,081,000	1,589,000	1,220,000	851,000	678,000
Operating Expenses	17.5%	47,232,000	40,208,000	43,280,000	42,621,000	37,525,000	36,522,000	34,692,000	38,381,000	31,711,000	26,983,500	24,863,000	29,339,000	18,689,000	14,941,000	13,525,000	8,531,000	8,243,000	-	7,697,000	5,995,000
S&GA Expenses	-100.0%	-	12,380,500	12,642,000	13,435,000	11,927,000	11,101,000	10,760,000	11,471,000	10,615,000	9,597,500	8,761,000	15,101,000	7,046,000	5,729,000	4,799,000	2,394,000	2,418,000	-	2,699,000	2,093,000
R&D Expenses	24.1%	34,529,000	27,827,500	30,638,000	29,186,000	25,598,000	25,421,000	23,932,000	26,910,000	21,096,000	17,386,000	16,102,000	14,238,000	11,643,000	9,212,000	8,726,000	6,137,000	5,825,000	-	4,998,000	3,902,000
EBITDA Margin	-19.9%	-10.30	-8.59	-0.86	-0.30	0.12	0.56	0.77	0.79	0.78	0.73	0.16	-6.14	-5.12	-	-	-	-	-	-	-
Income Taxes	-6.3%	2,214,000	2,362,500	-1,181,000	1,232,000	1,199,000	2,293,000	-2,977,000	2,817,000	49,951,000	39,172,000	2,771,000	-	-	-	-8,000	-50,000	2,000	-	29,000	58,000
Earnings Before Taxes	-27.7%	-36,002,000	-28,188,000	-33,422,000	-33,068,000	-14,352,000	22,746,000	-1,986,000	8,443,000	119,533,000	224,044,000	72,413,000	-26,459,000	-13,534,000	-14,903,000	-10,688,000	-7,252,000	-	-	-6,892,000	-5,697,000
EBT Margin	-19.9%	-10.38	-8.66	-0.87	-0.31	0.12	0.56	0.77	0.79	0.78	0.73	0.16	-6.19	-5.17	-	-	-	-	-	-	-
Net Income	-25.1%	-38,216,000	-30,550,500	-32,241,000	-34,300,000	-15,551,000	20,453,000	991,000	5,626,000	69,582,000	184,872,000	69,642,000	-26,459,000	-13,534,000	-14,904,000	-10,680,000	-7,202,000	-5,247,000	-5,376,000	-6,921,000	-5,755,000
Net Income Margin	-20.1%	-10.74	-8.94	-0.93	-0.33	0.09	0.36	0.57	0.61	0.60	0.61	0.13	-6.19	-5.16	-	-	-	-	-	-	-
Free Cashflow	-119.9%	-33,345,000	-15,161,000	-34,641,000	-30,246,000	-26,674,000	-27,290,000	-29,779,000	-30,833,000	-24,229,000	-58,978,000	604,471,000	-18,656,000	-14,878,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-5.7%	630	668	678	704	728	755	778	815	850	885	922	319	333	345	351	145	31.00
Current Assets	-12.8%	480	551	619	615	615	628	769	805	841	875	914	310	325	340	346	140	26.00
Cash Equivalents	-41.5%	147	251	204	216	225	285	752	792	824	849	900	303	322	336	340	137	20.00
Net PPE	12.1%	5.00	5.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	1.00	1.00	1.00
Liabilities	-4.1%	89.00	92.00	79.00	80.00	76.00	92.00	144	177	224	332	550	29.00	20.00	21.00	15.00	12.00	15.00
Current Liabilities	-11.1%	36.00	40.00	28.00	30.00	26.00	42.00	94.00	125	174	304	542	21.00	12.00	15.00	10.00	8.00	13.00
Shareholder's Equity	-5.9%	541	575	598	624	652	663	634	637	626	553	372	289	313	323	336	-	-
Retained Earnings	-30.7%	86.00	125	155	187	222	237	217	216	210	141	-44.20	-113	-87.43	-73.90	-58.99	-48.31	-35.86
Additional Paid-In Capital	1.6%	471	464	456	449	442	436	429	424	418	413	407	403	400	396	394	1.00	-
Shares Outstanding	0.0%	36.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	35.00	35.00	35.00	35.00	-	-	-	-	-
Float	-	-	-	-	-	-	-	-	-	855	-	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	-135.4%	-32,400	-13,765	-33,890	-29,546	-26,555	-27,173	-29,696	-30,322	-24,002	-58,816	605,001	-18,255	-14,790	-5,464	-10,231	-10,002	521	-	-	-
Share Based Compensation	1.0%	7,263	7,193	7,057	6,964	5,807	5,885	5,723	5,760	4,193	4,041	3,942	3,227	2,584	2,042	1,714	350	186	-	-	-
Cashflow From Investing	-213.1%	-69,600	61,556	22,693	20,103	-31,694	-445,120	-105	-514	-323	-161	-532	-458	-91.00	-134	-105	-101	-37.00	-	-	-
Cashflow From Financing	-92.8%	22.00	307	10.00	218	578	1,374	-1.00	278	333	2,356	441	195	667	833	212,873	-1,106	127,739	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ITOS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
License and collaboration revenue	$ 0	$ 12,595
Total revenue	0	12,595
Operating expenses:
Research and development expenses	34,529	25,598
General and administrative expenses	12,703	11,927
Total operating expenses	47,232	37,525
Loss from operations	(47,232)	(24,930)
Other income and expenses:
Grant income	949	735
Research and development tax credits	802	343
Interest income	7,386	7,851
Other income , net	2,093	1,649
Loss before income tax expense	(36,002)	(14,352)
Income tax expense	(2,214)	(1,199)
Net loss	$ (38,216)	$ (15,551)
Basic net loss per share	$ (1.07)	$ (0.44)
Diluted net loss per share	$ (1.07)	$ (0.44)
Weighted-average common shares outstanding - basic	35,843,116	35,716,037
Weighted-average common shares outstanding - diluted	35,843,116	35,716,037
Net Income (Loss)	$ (38,216)	$ (15,551)
Foreign currency translation adjustments	(2,265)	(2,006)
Unrealized (loss) gain on available-for-sale securities	(832)	102
Comprehensive loss	$ (41,313)	$ (17,455)

ITOS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 146,648	$ 251,177
Short-term investments (amortized cost of $302,914)	302,496	280,739
Grants receivable	130	0
Research and development tax credits receivable	732	135
Refundable income taxes	5,058	6,365
Prepaid expenses and other currents assets	25,322	12,236
Total current assets	480,386	550,652
Property and equipment, net	5,264	4,696
Long-term investments (amortized cost of $132,987)	132,587	100,539
Research and development tax credits receivable, net of current portion	4,615	4,508
Restricted cash	271	274
Right of use assets	5,804	6,036
Other assets	842	883
Total assets	629,769	667,588
Current liabilities:
Accounts payable	5,530	11,293
Accrued expenses and other current liabilities	16,659	7,058
Accrued personnel expenses	4,864	8,562
Payable for investments	6,065	9,787
Deferred income	1,178	2,063
Lease liabilities	1,262	1,251
Total current liabilities	35,558	40,014
Grants repayable, net of current portion	6,469	6,609
Lease liabilities, net of current portion	4,562	4,807
Unrecognized tax benefits	41,980	40,930
Total liabilities	88,569	92,360
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock, $0.001 par value: 150,000,000 shares authorized at March 31, 2024 and December 31, 2023; 35,843,756 and 35,838,080 shares issued and outstanding, respectively	36	36
Additional paid-in capital	471,084	463,799
Accumulated other comprehensive loss	(16,337)	(13,240)
Retained earnings	86,417	124,633
Total stockholders’ equity	541,200	575,228
Total liabilities and stockholders’ equity	$ 629,769	$ 667,588

About iTeos Therapeutics, Inc.

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Michel Detheux Ph.D.
WEBSITE	iteostherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	125

iTeos Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for iTeos Therapeutics, Inc.? What does ITOS stand for in stocks?

ITOS is the stock ticker symbol of iTeos Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of iTeos Therapeutics, Inc. (ITOS)?

As of Tue May 14 2024, market cap of iTeos Therapeutics, Inc. is 603.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ITOS stock?

You can check ITOS's fair value in chart for subscribers.

What is the fair value of ITOS stock?

You can check ITOS's fair value in chart for subscribers. The fair value of iTeos Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of iTeos Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ITOS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is iTeos Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ITOS is over valued or under valued. Whether iTeos Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact iTeos Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ITOS.

What is iTeos Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 14 2024, ITOS's PE ratio (Price to Earnings) is -4.46 and Price to Sales (PS) ratio is 47.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ITOS PE ratio will change depending on the future growth rate expectations of investors.